PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
 

The abstract #1529 titled "Activity of lurbinectedin (PM1183) as single agent and in combination in patients with advanced small cell lung cancer (SCLC)" will be presented on September 11^th. In this abstract, a cohort B will be presented using a new dosing regimen as compared to cohort A that was presented at the American Society of Clinical Oncology Annual Meeting in 2015. The efficacy of PM1183 in this cohort of patients with advanced small cell lung cancer was evidenced by a progression free survival (PFS) of 5.3m with an objective response rate of 37%. The safety profile in Cohort B in terms of the rate of febrile neutropenia, thrombocytopenia and anemia was markedly improved compared to cohort A.

Lurbinectedin is currently enrolling the pivotal phase III ATLANTIS trial in this setting with an expected completion of enrollment around first half of 2018. Dr. Arturo Soto, Director of the Clinical Department at PharmaMar Oncology Business Unit, added "small cell lung cancer is a devastating disease and the only approved drug for advanced disease is Topotecan. As far as we know these results with lurbinectedin offer the longest PFS seen in this setting and we hope to be able to offer these patients a new treatment option, if we confirm this data in the pivotal clinical trial."

Also, during this meeting, PharmaMar will make various presentations in which it will manifest the latest breakthroughs in the clinical development of Yondelis® (trabectedin). A matching, indirect, adjusted comparison of Yondelis® and pazopanib for the treatment of advanced and metastatic leiomyosarcomas; a prospective Phase IV trial that evaluates the use of Yondelis® combined with pegylated liposomal doxorubicin in the clinic to measure the toxicity and the efficacy when it is administered to women with platinum sensitive ovarian cancer, following the marketing authorization (OVA-YOND); along with the observational, prospective study Y-IMAGE, that evaluates the routine, real-life use of trabectedin in patients with advanced soft tissue sarcoma across Europe, as well as a preclinical study on a possible new biomarker to determine the advance of liposarcomas.    

Principle studies that will be presented at ESMO 2017  

PM1183 

• Activity of lurbinectedin in SCLC (alone and in combination) from different phase I and phase II studies (#1529PD) 

Poster Discussion Session. 11.09.2017, 14:45 - 16:15, Pamplona Auditorium

Lead author: María Eugenia Olmedo, MD, et al. Ramón y Cajal Universitary Hospital, Madrid, Spain  

Yondelis^® (trabectedin)  

• A matching-adjusted indirect comparison of trabectedin and pazopanib for the treatment of advanced, metastatic, leiomyosarcomas (#1484PD)  

Poster Discussion Session. 11.09.2017, 11:00 - 12:30, Bilbao Auditorium

Lead author: Robin Jones, MD, et al. Sarcoma Unit, Royal Marsden Hospital, Institute of Cancer Research, London, Great Britain

• An observational, multicenter, open-label study of trabectedin plus PLD in patients with platinum-sensitive recurrent ovarian cancer (#967P) 

Poster Display Session.  09.09.2017, 13:15 - 14:15, Hall 8

Lead author: D. Reichert, MD et al. Gemeinschaftspraxis für Onkologie, Germany

• The routine real-life use of trabectedin (T) in patients with advanced soft tissue sarcoma (STS) across Europe: an analysis of overall vs. per country results from Y-IMAGE study (#1499P) 

Poster Display Session. 11.09.2017, 13:15 - 14:15, Hall 8

Lead author: N. Penel, MD et al. Centre Oscar Lambret, Lille, France

• Outcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study (#966P) 

Poster Display Session.  09.09.2017, 13:15 - 14:15, Hall 8

Lead author: F. Selle (Paris, France)

• Geriatric assessment of elderly chemotherapy-naïve patients treated with trabectedin for advanced soft tissue sarcoma: E-TRAB study (#1525TiP) 

Poster Display Session. 11.09.2017, 13:15 - 14:15, Hall 8

Lead author: B. Kasper, MD et al. Interdisziplinäres Tumorzentrum, Universitätsklinikum Manheim, Germany

• HMGA1 is a new biomarker of liposarcoma progression (#1689P) 

Poster Display Session. 11.09.2017, 13:15 - 14:15, Hall 8

Lead author: Loria R, MD et al. Cellullar network and molecular therapeutic target unit, preclinical models and new therapeutic agents unit

Contact: Paula Fernandez, pfalarcon@pharmamar.com , Media Relations (+34 638 79 62 15) and Investor Relations (+34 914444500)